Hematopoietic cell transplantation in the management of myelodysplastic syndrome: An evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on practice guidelines Review
| Authors: | DeFilipp, Z.; Ciurea, S. O.; Cutler, C.; Robin, M.; Warlick, E. D.; Nakamura, R.; Brunner, A. M.; Dholaria, B.; Walker, A. R.; Kröger, N.; Bejanyan, N.; Atallah, E.; Tamari, R.; Solh, M. M.; Percival, M. E.; de Lima, M.; Scott, B.; Oran, B.; Garcia-Manero, G.; Hamadani, M.; Carpenter, P.; DeZern, A. E. |
| Review Title: | Hematopoietic cell transplantation in the management of myelodysplastic syndrome: An evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on practice guidelines |
| Abstract: | The sole curative therapy for myelodysplastic syndrome (MDS) is allogeneic hematopoietic cell transplantation (HCT). Here this therapeutic modality is reviewed and critically evaluated in the context of the evidence. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of MDS experts comprising transplantation and nontransplantation physicians developed consensus treatment recommendations. This review summarizes the standard MDS indications for HCT and addresses areas of controversy. Recent prospective trials have confirmed that allogeneic HCT confers survival benefits in patients with advanced or high-risk MDS compared with nontransplantation approaches, and the use of HCT is increasing in older patients with good performance status. However, patients with high-risk cytogenetic or molecular mutations remain at high risk for relapse. It is unknown whether administration of novel therapies before or after transplantation may decrease the risk of disease relapse in selected populations. Ongoing and future studies will investigate revised approaches to disease risk stratification, patient selection, and post-transplantation approaches to optimize allogeneic HCT outcomes for patients with MDS. © 2022 The American Society for Transplantation and Cellular Therapy |
| Keywords: | cancer survival; aged; transplantation, homologous; gene mutation; genetics; cancer recurrence; advanced cancer; united states; outcome assessment; prospective study; consensus; evidence based practice; recurrence; cytogenetics; practice guideline; hematopoietic stem cell transplantation; high risk patient; risk assessment; myelodysplastic syndrome; genetic susceptibility; transplantation conditioning; medical society; recurrent disease; allogeneic hematopoietic stem cell transplantation; allotransplantation; myelodysplastic syndromes; allogeneic hematopoietic cell transplantation; guideline; evidence-based review; humans; human; article |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 29 |
| Issue: | 2 |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-02-01 |
| Start Page: | 71 |
| End Page: | 81 |
| Language: | English |
| DOI: | 10.1016/j.jtct.2022.11.014 |
| PUBMED: | 36436780 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 1 March 2023 -- Source: Scopus |
